Therapeutics and molecular medicine

This meeting focuses on the biology and signalling of the class I isoforms of PI3K, and the drugs that have been generated to interfere with their function in disease. After some challenging years in PI3K pathway drug development, good progress has recently been made, with 3 PI3K inhibitors now approved for oncology and several others in the registration pipeline. Basic science investigations continue to provide new insight into the clinical observations.